15th Mar 2013 07:00
Cyprotex PLC ("Cyprotex" or the "Company")
Notice of Results
15 March 2013 - Cyprotex PLC (AIM:CRX), the specialist preclinical contract research organisation (CRO) will announce its final results for the year ended 31 December 2012 on 21 March 2013.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | www.cyprotex.com |
N+1 Singer (Nomad and broker to Cyprotex) | Tel: +44 (0)20 7496 3000 |
Shaun Dobson Jenny Wyllie
| [email protected]@n1singer.comwww.nplus1singer.com |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Simon Conway Mo Noonan | www.fticonsulting.com
|
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.
Related Shares:
CRX.L